NLS Pharmaceutics AG is a biotechnology business based in the US. NLS Pharmaceutics shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars. NLS Pharmaceutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.53 |
|---|---|
| 52-week range | $0.46 - $3.72 |
| 50-day moving average | $0.69 |
| 200-day moving average | $1.37 |
| Wall St. target price | $7.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5305 from 2022-07-01
| 1 week (2022-06-28) | -12.95% |
|---|---|
| 1 month (2022-06-06) | -18.36% |
| 3 months (2022-04-06) | -55.79% |
| 6 months (2022-01-06) | -58.55% |
| 1 year (2021-07-06) | -82.66% |
|---|---|
| 2 years (2020-07-02) | N/A |
| 3 years (2019-07-02) | N/A |
| 5 years (2017-07-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -212.52% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.04 |
| Market capitalisation | $10.4 million |
TTM: trailing 12 months
We're not expecting NLS Pharmaceutics to pay a dividend over the next 12 months.
You may also wish to consider:
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.